There are two ongoing ph III trials with Aducanumab. Based on the large number enrolled and the start date of the trials we'd have heard of serious toxicity issues by now.
The Engage and Emerge trials are being done on a global scale. Qualified patients will participate in one or the other, but, not both. Go to this link if you have a family member you'd like to get into the trial. https://www.aducanumabclinicaltrials.com/about-these-studies
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE) Study Start: August 2015 178 locations
https://clinicaltrials.gov/ct2/show/NCT02477800?term=aducanumab&rank=5&submit_fld_opt=
Estimated Enrollment: 1350
Study Start Date: August 2015
Estimated Study Completion Date: February 2022
Estimated Primary Completion Date: February 2020 (Final data collection date for primary outcome measure)
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE) Study Start: September 2015 173 locations
https://clinicaltrials.gov/ct2/show/NCT02484547?term=aducanumab&rank=4&submit_fld_opt=
Estimated Enrollment: 1350
Study Start Date: September 2015
Estimated Study Completion Date: February 2022
Estimated Primary Completion Date: February 2020 (Final data collection date for primary outcome measure)
It's going to be a few years before we get results on efficacy from these ph III's.
Ph I side effects
Aducanumab | ALZFORUM
http://www.alzforum.org/therapeutics/aducanumab
There is no ph II listed on clinical trials.gov
Only ph I and ph III...
I don't hold long or short here... just watching Alzheimer's trials with hope that one of them come through with some meaningful therapies.
In Reply to 'Cbdpotential'
http://www.fiercebiotech.com/r-d/updated-a-setback-biogen-s-mid-range-dose-of-aducanumab-flops-alzheimer-s-study
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Recent BIIB News
- UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 • GlobeNewswire Inc. • 09/24/2024 05:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 11:31:32 AM
- Biogen Board Appoints Two New Independent Directors • GlobeNewswire Inc. • 09/12/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 10:00:08 AM
- Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA • GlobeNewswire Inc. • 09/04/2024 11:30:34 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 05:00:40 PM
- Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain • PR Newswire (US) • 08/22/2024 09:10:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/16/2024 10:40:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:30:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:11:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:55:02 AM
- Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen • PR Newswire (US) • 07/31/2024 01:00:00 PM
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC • GlobeNewswire Inc. • 07/30/2024 09:15:17 PM
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International Conference (AAIC) 20 • PR Newswire (US) • 07/30/2024 09:00:00 PM
- Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union • GlobeNewswire Inc. • 07/26/2024 11:20:38 AM
- Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor • Business Wire • 07/24/2024 10:30:00 AM
- The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB • PR Newswire (US) • 07/17/2024 09:45:00 AM
- Biogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB • PR Newswire (US) • 07/16/2024 08:00:00 AM
- Biogen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BIIB • PR Newswire (US) • 07/12/2024 09:45:00 AM
- July 22, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against BIIB • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Biogen Completes Acquisition of Human Immunology Biosciences • GlobeNewswire Inc. • 07/02/2024 01:16:51 PM
- Nike Stock Drops 14% in Pre-Market; Nokia Acquires Infinera for $2.3 Billion, and More News • IH Market News • 06/28/2024 10:50:25 AM
- The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 06/28/2024 09:45:00 AM
- “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China • GlobeNewswire Inc. • 06/27/2024 11:39:36 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM